Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV human immunoglobulin (pH4) for primary immune thrombocytopenia
CTR20160321Phase 3Completed
- Sponsor
- Xinjiang Deyuan Bioengineering Co., Ltd.
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous human immunoglobulin (pH4) in immune thrombocytopenia (ITP), sponsored by Xinjiang Deyuan Bioengineering Co., Ltd.. Started Jun 2016; status: completed.
02
Drugs
intravenous human immunoglobulin (pH4)
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20160321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160321.